Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2002

View Archived Issues

Roflumilast proven safe and effective in exercise-induced asthma

Intravitreal 2-methoxyestradiol implants effective in rat model of CNV

New data on the use of thymosin beta4 in the treatment of eye wounds

Spotlight on a new type of anti-HSV drug

Basic and clinical results reported for the novel immunosuppressant FTY-720

Administration of IL-2 receptor antagonist reduces toxicities of tacrolimus

Recent data on the new immunosuppressant LF-15-0195 presented at Transplant 2002

The role of statins in organ transplantation

First launch for Neulasta in April

Injectable COX-2-specific painkiller launched for the first time

FDA approves recommended starting doses of atorvastatin

Regulatory approval sought for NMP22 BladderChek diagnostic for bladder cancer

TACE and MMP inhibitors reported by Wyeth investigators

A new series of 5-HT7 receptors and their uses disclosed by Meiji Seika

CpG-7909 enters phase I/II trial in stage IV renal cell carcinoma

Fujisawa submits NDA for antifungal micafungin

Approvable letter for Cialis in erectile dysfunction

NeuroSearch will not advance NS-3728 into phase II for sickle cell anemia

King Pharmaceuticals patents novel, potent adenosine receptor modulators

Vasomax MAA to be withdrawn in U.K.

First birth control patch Ortho Evra launched

CCR3 receptor antagonists jointly reported by Yamanouchi and Toray

Shire submits NDA for Foznol

Patient enrollment under way in Canadian phase III trials of Antegren in MS

Scientists at NeoRx identify new anticancer conjugates

FDA approves Benicar for treatment of hypertension

New series of peptide compounds synthesized at Enzyme Systems Products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...